![Pearls in a shell](/media/hbmpartners/styles/hero_small/public/images/hero-images/hero-portfolio-companies.jpg?h=14832055&itok=DIQpNLis)
Upstream Bio
Industry
Inflammation and Allergy
Website
HBM contact
Company status
Private
Upstream Bio, a clinical-stage biotech company advancing new therapies to treat allergy and inflammation, is developing UPB-101, a clinical-stage monoclonal antibody that inhibits the TSLP receptor.
![Logo Upstream Bio](/media/hbmpartners/images/portfolio/logo/upstream-blue.png)